

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ABG WTT-MedAvail Ltd</u> (Last) (First) (Middle) <u>UNIT 3002-3004, 30TH FLOOR</u> <u>GLOUCESTER TOWER, THE LANDMARK, CENTRAL</u> (Street) <u>HONG KONG K3</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MedAvail Holdings, Inc. [MDVL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/14/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/14/2020		P		7,922	A	\$12.2443 ⁽¹⁾	3,790,002	I	See footnote ⁽²⁾
Common Stock	12/14/2020		P		6,535	A	\$12.2443 ⁽¹⁾	2,841,625	I	See footnote ⁽³⁾
Common Stock	12/15/2020		P		5,184	A	\$12.4955 ⁽⁴⁾	3,795,186	I	See footnote ⁽²⁾
Common Stock	12/15/2020		P		4,276	A	\$12.4955 ⁽⁴⁾	2,845,901	I	See footnote ⁽³⁾
Common Stock	12/15/2020		P		10,942	A	\$13.0821 ⁽⁵⁾	3,806,128	I	See footnote ⁽²⁾
Common Stock	12/15/2020		P		9,027	A	\$13.0821 ⁽⁵⁾	2,854,928	I	See footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>ABG WTT-MedAvail Ltd</u> (Last) (First) (Middle) <u>UNIT 3002-3004, 30TH FLOOR</u> <u>GLOUCESTER TOWER, THE LANDMARK, CENTRAL</u> (Street) <u>HONG KONG K3</u> (City) (State) (Zip)	1. Name and Address of Reporting Person* <u>Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.</u>
--	---

(Last)	(First)	(Middle)
UNIT 3002-3004, 30TH FLOOR		
GLOUCESTER TOWER, THE LANDMARK, CENTRAL		
<hr/>		
(Street)		
HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
ABG-WTT Global Life Science Capital Partners GP, L.P.		
<hr/>		
(Last)	(First)	(Middle)
UNIT 3002-3004, 30TH FLOOR		
GLOUCESTER TOWER, THE LANDMARK, CENTRAL		
<hr/>		
(Street)		
HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
ABG-WTT Global Life Science Capital Partners GP Ltd		
<hr/>		
(Last)	(First)	(Middle)
UNIT 3002-3004, 30TH FLOOR		
GLOUCESTER TOWER, THE LANDMARK, CENTRAL		
<hr/>		
(Street)		
HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
ABG Management Ltd.		
<hr/>		
(Last)	(First)	(Middle)
UNIT 3002-3004, 30TH FLOOR		
GLOUCESTER TOWER, THE LANDMARK, CENTRAL		
<hr/>		
(Street)		
HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
Yu Fan		
<hr/>		
(Last)	(First)	(Middle)
UNIT 3002-3004, 30TH FLOOR		
GLOUCESTER TOWER, THE LANDMARK, CENTRAL		
<hr/>		
(Street)		
HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
Ally Bridge MedAlpha Master Fund L.P.		
<hr/>		
(Last)	(First)	(Middle)
430 PARK AVENUE, 12TH FLOOR,		
<hr/>		
(Street)		
NEW YORK	NY	10022
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
--	--	--

Ally Bridge MedAlpha Management L.P.

(Last) (First) (Middle)
430 PARK AVENUE, 12TH FLOOR,

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person*
Ally Bridge MedAlpha Management GP, LLC

(Last) (First) (Middle)
430 PARK AVENUE, 12TH FLOOR,

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person*
Ally Bridge Group (NY) LLC

(Last) (First) (Middle)
430 PARK AVENUE, 12TH FLOOR,

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.0125 to \$12.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
3. These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.29 to \$12.995. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$13.00 to \$13.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Ally Bridge Group-WTT
Global Life Science Capital
Partners, L.P., By: ABG-WTT
Global Life Science Capital
Partners GP, L.P., its general
partner, By: ABG-WTT
Global Life Science Capital
Partners GP Limited, its
general partner, By: /s/ Fan
Yu, Director
ABG-WTT Global Life
Science Capital Partners GP,
L.P., By: ABG-WTT Global
Life Science Capital Partners
GP Limited, its general
partner, By: /s/ Fan Yu,
Director
ABG-WTT Global Life
Science Capital Partners GP
Limited, By: /s/ Fan Yu,
Director
Ally Bridge MedAlpha Master
Fund L.P., By: Ally Bridge
MedAlpha General Partner
L.P., its general partner, By:
Ally Bridge MedAlpha GP,

12/16/2020
12/16/2020
12/16/2020

<u>LLC, its general partner, By:</u>	
<u>/s/ Fan Yu, Manager</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Management L.P., By: Ally</u>	
<u>Bridge MedAlpha</u>	
<u>Management GP, LLC, its</u>	<u>12/16/2020</u>
<u>general partner, By: ABG</u>	
<u>Management Ltd., its</u>	
<u>managing member, By: /s/ Fan</u>	
<u>Yu, Director</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Management GP, LLC, By:</u>	
<u>ABG Management Ltd., its</u>	<u>12/16/2020</u>
<u>managing member, By: /s/ Fan</u>	
<u>Yu, Director</u>	
<u>Ally Bridge Group (NY) LLC,</u>	
<u>By: ABG Management Ltd.,</u>	<u>12/16/2020</u>
<u>its managing member, By: /s/</u>	
<u>Fan Yu, Director</u>	
<u>ABG Management Ltd., By:</u>	<u>12/16/2020</u>
<u>/s/ Fan Yu, Director</u>	
<u>ABG WTT-MedAvail</u>	
<u>Limited, By: /s/ Charles Chon,</u>	<u>12/16/2020</u>
<u>Director</u>	
<u>/s/ Fan Yu</u>	<u>12/16/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.